Nav interneta savienojuma — tiek rādīta saglabātā lapas versija.

10x Genomics, Inc…

USUSD
← Uz Akciju Filtru
US:TXGLSE:0A88

10x Genomics, Inc. (US:TXG) — Biotechnology: Laboratory Analytical Instruments. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.

Par Uzņēmumu

Tīmekļvietne
10xgenomics.com
Nozare
Industrials · Biotechnology: Laboratory Analytical Instruments
Galvenā Mītne
Pleasanton, United States
Izpilddirektors
Serge Saxonov
Darbinieki
1 178
Dibināts
2012
Apgrozībā Esošās Akcijas
120.21 milj.
Brīvā Apgrozība
118.19 milj.
Tirgus Kapitalizācija
11.53 mljrd. USD
Iekšējās Personas
1.46%
Institucionālie Investori
120.2%
Nozare (SIC)
Laboratory Analytical Instruments
Juridiskā Forma
XTIQ
ISIN
US88025U1097
LEI
5493003Z6741WNLG7H43
P/E
zaudējumi
FCF
121 milj. USD
Parāds
0 USD
neto nauda
Peļņa un FCF — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
NAV
6.87 USD · P/NAV 10.2
Bilances Datums30.06.2026
Aktīvi1.03 mljrd. USD
− Saistības205 milj. USD
= NAV (Uzņēmuma Akcionāru Kapitāls)826 milj. USD
− Nemateriālā Vērtība6.92 milj. USD
− Nemateriālie Aktīvi61.2 milj. USD
= Materiālā NAV757 milj. USD
Akcijas120 212 296
NAV uz Akciju6.87 USD
Taustāmā NAV uz Akciju6.30 USD
Akcijas Cena (TXG)69.8900 USD
P/NAV10.18
NAV Vēsture
Bilances DatumsNAVNAV uz Akciju
30.06.2026826 milj. USD6.87 USD
31.03.2026814 milj. USD6.77 USD
31.12.2025796 milj. USD6.24 USD
30.09.2025785 milj. USD6.53 USD
30.06.2025773 milj. USD6.43 USD
31.03.2025707 milj. USD5.88 USD
31.12.2024710 milj. USD5.81 USD
30.09.2024723 milj. USD6.01 USD
Apraksts

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

reklāma

Biržas un Tikeri

BiržaTikerisValūtaCenaVeids
US USA StocksTXG galvenāUSD69.89 +0.04%parastās akcijas
LSE London Stock Exchange0A88 IOBUSD88.31 +0.00%parastās akcijas

Cena 3 Mēnešu Laikā

pieauguma diena krituma dienaUzbrauciet / pieskarieties dienai — atvēršanas, slēgšanas, augstākā un zemākā cena

Lielākie Akcionāri

TurētājsDaļaAkcijasPārskata Datums
FMR, LLC14.67%17.63 milj.2026-06-30
Blackrock Inc.8.99%10.8 milj.2026-06-30
ARK Investment Managemen…8.32%10 milj.2026-06-30
Vanguard Portfolio Manag…5.81%6.98 milj.2026-06-30
Quantinno Capital Manage…4.55%5.47 milj.2026-06-30
Vanguard Capital Managem…4.23%5.08 milj.2026-06-30
Price (T.Rowe) Associate…3.78%4.54 milj.2026-06-30
Sumitomo Mitsui Trust Gr…3.49%4.19 milj.2026-06-30
Amova Asset Management A…3.49%4.19 milj.2026-06-30
VANGUARD INDEX FUNDS-Van…2.94%3.53 milj.2026-06-30
Morgan Stanley2.79%3.35 milj.2026-06-30
iShares Trust-iShares Ru…2.53%3.04 milj.2026-07-31
ARK ETF Trust-ARK Genomi…2.53%3.04 milj.2026-08-31
ARK ETF Trust-ARK Innova…2.5%3.01 milj.2026-08-31
VANGUARD INDEX FUNDS-Van…2.12%2.55 milj.2026-06-30
Fidelity Select PORT.s-S…1.66%2 milj.2026-07-31
Fidelity Rutland Square…1.37%1.65 milj.2026-07-31
Fidelity Select Portfoli…1.34%1.61 milj.2026-07-31
VANGUARD INDEX FUNDS-Van…1.22%1.47 milj.2026-06-30
T. Rowe Price New Horizo…1.21%1.46 milj.2026-06-30
SAXONOV SERGE WILSON (Ch…≈1.11%1.34 milj.2026-09-22
HINDSON BENJAMIN J (Pres…≈0.41%488 1822026-08-24
STUELPNAGEL JOHN R (Dire…≈0.27%328 4362026-09-03
TAICH ADAM (Chief Financ…≈0.26%316 3442026-09-09
MATEO ALAN V. (Director)≈0.07%85 8772026-06-04
KOSARAJU SRIDHAR (Direct…≈0.06%68 2782026-06-04
POPOVITS KIMBERLY J (Dir…≈0.03%37 4452026-06-04
TEICHMANN SARAH A. (Dire…≈0.02%28 0582026-08-14
SULIMAN SHEHNAAZ (Direct…≈0.02%23 7922026-09-22